![David Maggs](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Maggs
Director Ejecutivo en Abvance Therapeutics, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Steve Daly | M | - |
Abvance Therapeutics, Inc.
![]() Abvance Therapeutics, Inc. BiotechnologyHealth Technology Abvance Therapeutics, Inc. is a pharmaceutical company that aims to improve diabetes control and reduce the risk of hypoglycemia. The company is based in Reno, NV. The company's Abv100 platform is designed to replace rapid acting insulin and can be used by any patient type, including those with type 1 and type 2 diabetes who use injections or pumps. The platform protects against hypoglycemia, allowing for safer use of insulin and better control of diabetes, which can lead to improved long-term health outcomes. The company was founded in 2016 by Alan Cherrington, David Maggs, and Soumitra Ghosh. David Maggs has been the CEO since 2016. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Michael D. Dale | M | 64 | 2 años | |
Robert Crane | M | 65 | 11 años | |
Stuart Randle | M | 64 | 11 años | |
Daniel Moore | M | 63 | 6 años | |
Andrew Levine | M | - | 11 años | |
Alan Cherrington | M | - |
Abvance Therapeutics, Inc.
![]() Abvance Therapeutics, Inc. BiotechnologyHealth Technology Abvance Therapeutics, Inc. is a pharmaceutical company that aims to improve diabetes control and reduce the risk of hypoglycemia. The company is based in Reno, NV. The company's Abv100 platform is designed to replace rapid acting insulin and can be used by any patient type, including those with type 1 and type 2 diabetes who use injections or pumps. The platform protects against hypoglycemia, allowing for safer use of insulin and better control of diabetes, which can lead to improved long-term health outcomes. The company was founded in 2016 by Alan Cherrington, David Maggs, and Soumitra Ghosh. David Maggs has been the CEO since 2016. | - |
Jennifer D. Haldeman | F | 59 |
Parke, Davis & Co. LLC
| 9 años |
Mark C. Twyman | M | 63 | 3 años | |
Erin Moore | F | 49 | 3 años | |
Soumitra Ghosh | M | - |
Abvance Therapeutics, Inc.
![]() Abvance Therapeutics, Inc. BiotechnologyHealth Technology Abvance Therapeutics, Inc. is a pharmaceutical company that aims to improve diabetes control and reduce the risk of hypoglycemia. The company is based in Reno, NV. The company's Abv100 platform is designed to replace rapid acting insulin and can be used by any patient type, including those with type 1 and type 2 diabetes who use injections or pumps. The platform protects against hypoglycemia, allowing for safer use of insulin and better control of diabetes, which can lead to improved long-term health outcomes. The company was founded in 2016 by Alan Cherrington, David Maggs, and Soumitra Ghosh. David Maggs has been the CEO since 2016. | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 11 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- David Maggs
- Red Personal